TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 901–1,000 of 1,002
Migratory Engineering of T Cells for Cancer Therapy
Michaelides, S., Obeck, H., Kechur, D., Endres, S., & Kobold, S. (2022) · Vaccines · doi:10.3390/vaccines10111845 · Cited by 21
Hou, B., Ye, J., Li, J., Xu, Z., & Yu, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101661 · Cited by 22
Yang, M., Wang, F., Liang, H., Ji, G., Lian, Y., Zou, C., & Zhao, W. (2023) · Medicine Advances · doi:10.1002/med4.10 · Cited by 23
South, A. P., Laimer, M., Gueye, M., Sui, J. Y., Eichenfield, L. F., Mellerio, J. E., & Nyström, A. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.05.024 · Cited by 26
Li, M., Wu, B., Li, L., Lv, C., & Tian, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188945 · Cited by 25
Anderson, K. G., Braun, D. A., Buqué, A., Gitto, S. B., Guerriero, J. L., Horton, B. L., Keenan, B. P., Kim, T. S., Overacre-Delgoffe, A. E., Ruella, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006533 · Cited by 24
Immunomodulatory molecules in colorectal cancer liver metastasis
Kong, W.-S., Li, J.-J., Deng, Y., Ju, H., & Xu, R. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217113 · Cited by 23
TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness
Jiao, C., Meng, T., Zhou, C., Wang, X., Wang, P., Lü, M., Tan, X., Wei, Q., Ge, X., & Jin, J. (2020) · Aging · doi:10.18632/aging.103085 · Cited by 21
Huang, J. J., Corona, A. L., Dunn, B. P., Cai, E. M., Prakken, J. N., & Blobe, G. C. (2019) · Oncogene · doi:10.1038/s41388-018-0672-7 · Cited by 22
Macrophage heterogeneity and its interactions with stromal cells in tumour microenvironment
Cao, L., Meng, X., Zhang, Z., Liu, Z., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01201-z · Cited by 32
Andac-Aktas, A. B., & Calibasi‐Kocal, G. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1687556 · Cited by 29
“TGF-β is a principal inhibitor of NK cell function, reducing NKG2D and NKp46 expression and IFN-γ production via Smad signaling (Tauriello et al., 2018; Bruno et al., 2019; Chaudhry et al., 2022).”
InfluentialShi, H., & Yang, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.3902 · Cited by 22
Wang, Z., Hopson, L. M., Singleton, S. S., Yang, X., Jogunoori, W. S., Mazumder, R., Obias, V., Lin, P., Nguyen, B.-N. H., Yao, M. D., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166179 · Cited by 20
Jiang, Z., Zhou, Y., & Huang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813331 · Cited by 25
“Decreased T-cell infiltration has been reported to be associated with a poorer prognosis (13), and TGF-b signal limits the infiltration of T cells, forming a suppressed immune microenvironment (14, 15).”
BackgroundInnocenti, F., Yazdani, A., Rashid, N., Qu, X., Ou, F., Buren, S. V., Bertagnolli, M. M., Kabbarah, O., Blanke, C. D., Venook, A. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3202 · Cited by 19
Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 24
Fang, Y., & Su, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893716 · Cited by 19
“Inhibition of TGFb unleashes a potent and durable cytotoxic T-cell response against tumor cells, preventing metastasis (42).”
BackgroundZhang, H., Zhang, N., Dai, Z., Wang, Z., Zhang, X., Liang, X., Zhang, L., Feng, S., Wu, W., Ye, W., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13315 · Cited by 19
Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers
Gertych, A., Walts, A. E., Cheng, K., Liu, M., John, J., Lester, J., Karlan, B. Y., & Oršulić, S. (2022) · Cells · doi:10.3390/cells11233769 · Cited by 21
Cancer Stem Cell Relationship with Pro-Tumoral Inflammatory Microenvironment
Sípos, F., & Műzes, G. (2023) · Biomedicines · doi:10.3390/biomedicines11010189 · Cited by 24
Comprehensive characterization of TGFB1 across hematological malignancies
Wang, C., Zhang, Z., Zhang, Y., Zheng, L., Liu, Y., Yan, A., Zhang, Y.-C., Chang, Q.-H., Sha, S., & Xu, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-46552-8 · Cited by 26
Forces at play: exploring factors affecting the cancer metastasis
Riaz, F., Zhang, J., & Pan, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1274474 · Cited by 25
From biology to the clinic — exploring liver metastasis in prostate cancer
Ni, X., Yu, W., Li, X., Pan, J., Fang, B., Zhang, T., Lu, Y., Ye, D., & Zhu, Y. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00875-x · Cited by 25
“TGFβ shapes the immunosuppressive microenvironment and mediates immune escape, thereby promoting liver metastases 102 .”
Ghorbaninezhad, F., Nour, M. A., Farzam, O. R., Saeedi, H., Vanan, A. G., Bakhshivand, M., Jafarlou, M., Hatami‐Sadr, A., & Baradaran, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189281 · Cited by 29
Long, X., Deng, Z., Li, G., & Wang, Z. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0640-x · Cited by 23
Holstein, S. A., Al-Kadhimi, Z. S., Costa, L. J., Hahn, T., Hari, P., Hillengaß, J., Jacob, A. P., Munshi, N. C., Oliva, S., Pasquini, M. C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.09.015 · Cited by 20
Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme
Koliaraki, V., Henriques, A. R., Prados, A., & Kollias, G. A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190457 · Cited by 22
Xue, L., Bi, G., Zhan, C., Zhang, Y., Yuan, Y., & Fan, H. X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00835 · Cited by 20
Liu, J., Yu, F., Tan, Y., Huo, J.-P., Liu, Z., Wang, X., & Li, J. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4118 · Cited by 25
TGFβ Signaling in the Tumor Microenvironment
Goulet, C. R., & Pouliot, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_6 · Cited by 22
Chen, N., Han, X., Bai, X., Yin, B., & Wang, Y. (2020) · PubMed · Cited by 20
Xiao, S., Liu, X., Yuan, L., Chen, X., & Wang, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694003 · Cited by 21
“Recent studies have found that the activation of the stroma could exclude CD8+ T cells from the tumor parenchyma into the fibroblast- and collagen-rich peritumoral stroma (Salmon et al., 2012; Tauriello et al., 2018).”
BackgroundTong, H., Wei, H., Smith, A. O., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.802049 · Cited by 21
“They found that ICIs combined with Fruquitinib or Regorafenib (an antiangiogenic drug, the former combination works better than the latter and could significantly improve the progression-free survival of mCRC patients) (84), LDH-A inhibitors (85), MEK inhibitors (86, 87), celecoxib (an inhibitor of the cyclooxidase CO…”
BackgroundCorry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., Tsantoulis, P., Cortes-Lavaud, X., Amirkhah, R., Redmond, K. L., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326183 · Cited by 18
TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma
Xue, H.-Y., & Fang, W. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05843-4 · Cited by 23
Yao, H.-J., Luo, L., Li, R. Q., Zhao, Y., Zhang, L., Pešić, M., Cai, L., & Li, L. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189220 · Cited by 20
Wang, M., Zhao, Y., Xu, K., Liu, C., Zhong, H., Wu, Y., Zhang, K., & Wei, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617968 · Cited by 34
Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts
Liu, Y., Chen, X., Dai, Y., Jia, Y., Kieffer, Y., Xie, L., Zhou, Z., Tyler, L. A., Kim, A. C., Biffi, G., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.06.001 · Cited by 26
Neal, M. E. H., Bhangale, A. D., Birkeland, A. C., McHugh, J. B., Shuman, A. G., Rosko, A. J., Swiecicki, P. L., Spector, M. E., & Brenner, J. C. (2020) · Cancers · doi:10.3390/cancers12113081 · Cited by 21
Harnessing Carcinoma Cell Plasticity Mediated by TGF-β Signaling
Wang, X., & Thiery, J. P. (2021) · Cancers · doi:10.3390/cancers13143397 · Cited by 20
Jiang, A., Qin, Y., & Springer, T. A. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0593 · Cited by 20
Nie, H., Wang, H., Zhang, M., Ning, Y., Chen, X., Zhang, Z., Hu, X., Zhao, Q., Chen, P., Fang, J., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04474-4 · Cited by 20
Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy
Barcellos‐Hoff, M. H., & Gulley, J. L. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3750 · Cited by 21
Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 24
Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
Karlsson‐Parra, A., Kovacka, J., Heimann, E., Jorvid, M., Zeilemaker, S., Longhurst, S., & Suenaert, P. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2438-x · Cited by 19
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 21
“eral studies revealed that TGF-β signaling is associated with a lack of response to anti-PD-1 therapy and that inhibition of TGFβ signaling can sensitize colorectal cancer and urothelial cancer to anti-PD-1/PD-L1 therapy [117,118].”
BackgroundThapa, D., Huang, S., Muñoz, A. R., Yang, X., Bedolla, R. G., Hung, C., Chen, C., Huang, T. H. ‐., Liss, M. A., Reddick, R. L., et al. (2020) · Communications Biology · doi:10.1038/s42003-019-0720-z · Cited by 20
Abuwarwar, M. H., Baker, A. T., Harding, J. S., Payne, N. L., Nagy, A., Knoblich, K., & Fletcher, A. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041827 · Cited by 21
Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment
Xiong, J., Wang, H., & Wang, Q. (2021) · Advanced Biology · doi:10.1002/adbi.201900311 · Cited by 21
Engineering Cell‐Based Systems for Smart Cancer Therapy
Mirkhani, N., Gwisai, T., & Schuerle, S. (2021) · Advanced Intelligent Systems · doi:10.1002/aisy.202100134 · Cited by 18
Zhang, H., Chen, J., Bai, J., Zhang, J., Huang, S., Zeng, L., Zhou, P., Shen, Q., & Yin, T. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001226 · Cited by 23
Bian, Y., Chang, X., Hu, X., Li, B., Song, Y., Hu, Z., Wang, K., Wan, X., & Lu, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35727 · Cited by 19
Unraveling the role of cancer-associated fibroblasts in colorectal cancer
Cui, J., Ma, J., Gao, X., Sheng, Z.-M., Pan, Z., Shi, L., & Zhang, B. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i12.4565 · Cited by 20
The multi-faceted immune modulatory role of S100A4 in cancer and chronic inflammatory disease
Wong, T. K. S., Kang, R., & Yun, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1525567 · Cited by 29
Iwane, K., Nakanishi, Y., Muta, Y., Chen, J., Yasumura, K., Omatsu, M., Aoyama, N., Ikeda, M., Masui, Y., Cai, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66485-2 · Cited by 22
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 22
Iesato, A., & Nucera, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_14 · Cited by 20
Wu, Y., Liu, B., Lin, W., Zhao, R., Han, W., & Xie, J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.007 · Cited by 18
The Landscape of Nanovectors for Modulation in Cancer Immunotherapy
Volovăț, S. R., Lupaşcu-Ursulescu, C. V., Gheorghe, L., Volovat, C. D., Boboc, D., Scripcariu, D. V., Amurariti, F., Ştefănescu, C., Stolniceanu, C. R., Agop, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020397 · Cited by 26
Birrer, M. J., Fujiwara, K., Oaknin, A., Randall, L. M., Ojalvo, L. S., Valencia, C., & Ray-Coquard, I. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.814169 · Cited by 22
Kong, W., Liu, Z., Sun, M., Liu, H., Kong, C., Ma, J., Wang, R., & Qian, F. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215718 · Cited by 19
Computational pathology in ovarian cancer
Oršulić, S., John, J., Walts, A. E., & Gertych, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924945 · Cited by 22
Qu, R., Ye, F., Hu, S., Wang, B., Qin, S., Xiong, J., Fu, X., Li, L., & Cai, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04289-3 · Cited by 19
Flanagan, D. J., Amirkhah, R., Vincent, D. F., Gündüz, N., Gentaz, P., Cammareri, P., McCooey, A. J., McCorry, A. M. B., Fisher, N. C., Belnoue-Davis, H. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35134-3 · Cited by 21
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Role of tumor-associated macrophages in common digestive system malignant tumors
Shen, Y. G., Chen, J., Li, M., Xiang, Z., Wu, J., & Wang, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.596 · Cited by 21
Blom, A. M., Gialeli, C., Hagerling, C., Berntsson, J., Jirström, K., & Παπαδάκος, Κ. Σ. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167659 · Cited by 20
“Further, TGF-b is a well-documented factor that drives anti-PD-L1 resistance in colon cancer (46).”
BackgroundTargeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
Lewis, R. I., Stein, A. F. V., & Hallek, M. J. (2024) · Blood · doi:10.1182/blood.2023022861 · Cited by 18
TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance
Johansen, A. M., Forsythe, S. D., McGrath, C. T., Barker, G., Jimenez, H., Paluri, R. K., & Pasche, B. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0468 · Cited by 21
Analysis of the transcriptomic features of microsatellite instability subtype colon cancer
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5802-2 · Cited by 20
Roberts, S., Salmon, S. L., Steiner, D. J., Williams, C. M., Metzger, D. W., & Furuya, Y. (2019) · mBio · doi:10.1128/mbio.01335-19 · Cited by 19
Cell-mediated immune resistance in cancer
Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 25
“In a mouse model of colorectal cancer, the typically immunologically “cold” tumors secreted TGF-β to knock down Th1 differentiation and T cell infiltration([114]).”
BackgroundLOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGFβ signaling in colorectal cancer
Javanmard, A., Dokanehiifard, S., Bohlooli, M., & Soltani, B. M. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03145-6 · Cited by 18
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
Segovia, M., Russo, S., Girotti, M. R., Rabinovich, G. A., & Hill, M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13433 · Cited by 20
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers
Luckett, K. A., Cracchiolo, J. R., Krishnamoorthy, G. P., Leandro-Garcia, L. J., Nagarajah, J., Saqcena, M., Lester, R., Im, S.-Y., Zhao, Z., Lowe, S. W., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0017 · Cited by 21
Wang, S., Gu, L., Huang, L., Fang, J., Liu, Z., & Xu, Q. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.084 · Cited by 20
Oliveira, T. D., Ramakrishnan, M., Diamanti, M. A., Ziegler, P. K., Brombacher, F., & Greten, F. R. (2018) · Oncogene · doi:10.1038/s41388-018-0551-2 · Cited by 19
Mouse Models of Metastasis and Dormancy
Mahmoud, A., & Ganesh, K. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041386 · Cited by 20
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Robbins, Y., Friedman, J., Clavijo, P. E., Sievers, C., Bai, K., Donahue, R. N., Schlom, J., Sinkoe, A., Abdul Sater, H., Gulley, J. L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003113 · Cited by 17
Colon Fibroblasts and Inflammation: Sparring Partners in Colorectal Cancer Initiation?
Onfroy-Roy, L., Hamel, D., Malaquin, L., & Ferrand, A. (2021) · Cancers · doi:10.3390/cancers13081749 · Cited by 20
p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-β
Chen, S., Zhang, J., Shen, M., Han, X., Li, S., Hu, C., Wang, W., Luo, L., Du, L., Pang, D., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107848 · Cited by 17
Ye, Y., & Zheng, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785400 · Cited by 18
“In T-cell excluded mouse models, immune checkpoint-resistant MSS colorectal cancers and liver tumors were rendered susceptible to anti-PD1/PD-L1 therapy with a TGF-b blockade (31).”
BackgroundFan, Y., Zhou, Y., Lou, M., Li, X., Zhu, X., & Yuan, K. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s356841 · Cited by 28
“TGFβ1 can induce extracellular mesenchymal gene expression, resulting in a reactive stroma and dense extracellular mesenchyme forming a barrier that prevents infiltration of immune cells within the tumour, leading to a repulsed infiltrative phenotype with peritumoral or mesenchymal T-cell localisation.(62) PD-L1 is hi…”
BackgroundVisualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy
You, R., Artichoker, J., Ray, A., Velozo, H. G., Rock, D. A., Conner, K. P., & Krummel, M. F. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0594 · Cited by 18
Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment
Antoñana-Vildosola, A., Zanetti, S. R., & Palazón, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.004 · Cited by 18
From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer
Betge, J., & Jackstadt, R. (2022) · International Journal of Cancer · doi:10.1002/ijc.34297 · Cited by 19
“inhibition to rewire the TME of immunologically cold AKPS CRC metastases.(19) Modeling of rectal cancer by transplanting syngeneic organoids or stimulation of cancer associated fibroblasts (CAFs) with”
BackgroundWei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19
Liang, Z., Sun, R., Tu, P., Liang, Y., Li, L., Liu, F., Bian, Y., Yin, G., Zhao, F., Jiang, M. C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944286 · Cited by 18
Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer
Li, S., Hao, L., Zhang, J., Deng, J., & Hu, X. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00785-x · Cited by 17
Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential
Bao, L., Zhu, P., Mou, Y., Song, Y., & Ye, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1214675 · Cited by 17
Morris, M. T., Jain, A., Sun, B., Kurbatov, V., Muca, E., Zeng, Z., Jin, Y., Roper, J., Lü, J., Paty, P. B., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216384 · Cited by 19
Ryu, K., Seo, J.-A., Lee, K., Choi, J., Yoo, G., Ha, J.-H., & Ahn, M. R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060346 · Cited by 22
“…that CAFs promote the formation of an immunosuppressive environment directly through the secretion of several chemokines or other negative immune regulators [21,22] and indirectly by regulating the stiffness of the ECM, which decreases immune cell infiltration or immune cell extravasation [23].”
BackgroundRevealing the crucial roles of suppressive immune microenvironment in cardiac myxoma progression
Jiang, Z., Kang, Q., Qian, H., Xu, Z., Tong, H., Yang, J., Li, L., Li, R., Li, G., Chen, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01912-2 · Cited by 17
Luo, M. (2024) · American Journal of Cancer Research · doi:10.62347/myza2640 · Cited by 21
Hippo pathway in cancer cells induces NCAM1+αSMA+ fibroblasts to modulate tumor microenvironment
Thinyakul, C., Sakamoto, Y., Shimoda, M., Liu, Y., Thongchot, S., Reda, O., Nita, A., Sakamula, R., Sampattavanich, S., Maeda, A., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-07041-4 · Cited by 20
Smeby, J., Sveen, A., Bergsland, C. H., Eilertsen, I. A., Danielsen, S. A., Eide, P. W., Hektoen, M., Guren, M. G., Nesbakken, A., Bruun, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000523 · Cited by 21
Gachpazan, M., Kashani, H., Hassanian, S. M., Khazaei, M., Khorrami, S., Ferns, G. A., & Avan, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105114539 · Cited by 19
Susmi, T. F., Rahman, A., Khan, M. M. R., Yasmin, F., Islam, M. S., Nasif, O., Alharbi, S. A., Batiha, G. E., & Hossain, M. U. (2021) · BMC Cancer · doi:10.1186/s12885-021-08332-3 · Cited by 17
PTTG1 knockdown enhances radiation-induced antitumour immunity in lung adenocarcinoma
Chen, Z., Cao, K., Hou, Y., Lu, F., Li, L., Wang, L., Xia, Y., Zhang, L., Chen, H., Li, R., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119594 · Cited by 19
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy
Ishii, H., Afify, S. M., Hassan, G., Salomon, D. S., & Seno, M. (2021) · Cancers · doi:10.3390/cancers13102491 · Cited by 18
“They showed that increased TGF-β in the tumor microenvironment is a major mechanism of immune avoidance by promoting T cell elimination and blocking the acquisition of the T helper 1 (Th1) effector phenotype in advanced colorectal cancer [14].”
Background
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.